Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA autologous CAR T-cell injection
- Development stage
- Unknown
- Lead developer
- Beijing Gaobo Boren Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
BCMA Autologous CAR T-cell Injection is an investigational chimeric antigen receptor (CAR) T-cell therapy being developed by Beijing Boren Hospital. This autologous cell therapy involves the ex vivo genetic modification of a patient's own T-cells using a lentiviral vector (specifically the pCDH-BCMA CAR plasmid) to express a CAR targeting B-cell maturation antigen (BCMA). BCMA is a cell surface receptor highly expressed on malignant plasma cells in multiple myeloma and light chain (AL) amyloidosis. By redirecting T-cells to recognize and eliminate BCMA-expressing cells, the therapy aims to reduce the production of monoclonal light chains and prevent further organ damage. It is currently being evaluated in an early-phase clinical trial (NCT06983951) for patients with relapsed or refractory AL amyloidosis.
- Other names
- Targeted BCMA Autologous CART Cell InjectionAnti-BCMA chimeric antigen receptor autologous T cells
Beyond the preview
Go deeper on BCMA autologous CAR T-cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA autologous CAR T-cell injection.